



Dr. David M. Kovitz
L.D.S, D.D.S., F.A.S.C.H., F.I.C.D.{C}

The Dr. David M. Kovitz Visiting Professorship was established to stimulate interest and development in education, training and research in the area of cancer and diabetes. The fund supports a lectureship which provided the opportunity for distinguished scholars from around the world to interact with faculty, students and members of the Calgary community while visiting our University.

Dr. David M. Kovitz, a well-respected dentist and businessman in Calgary, originally established the endowment in 1988. The fund was matched by the Government of Alberta and received further support by his family and friends. In 1992, Dr. Kovitz passed away but through his gift to the University of Calgary, the Visiting Professorship is a lasting tribute to his commitment to excellence and the advancement of medical research and education.

Past Dr. David M. Kovitz Lecturers:

1992	Dr. Paul Talalay	2013	Dr. Philippe Froguel
1993	Dr. Edmond Fischer	2014	Dr. Morag Park
1994	Dr. Meng H. Tan	2015	Dr. Emil Unanue
1995	Dr. Frank Rauscher III	2016	Dr. Nada Jabado
1996	Dr. Joseph Bertino	2017	Dr. David Sutherland
1997	Dr. Ronald Klein		
1998	Dr. Trevor Powles		
1999	Dr. Robert Weinberg		
2000	Dr. Barry I. Posner		
2001	Dr. Morris J. Birnbaum		
2002	Dr. C. Ronald Kahn		
2003	Dr. Nader Abraham		
2004	Dr. Frances M. Ashcroft		
2005	Dr. Jeannette Ward		
2006	Dr. Edward H. Leiter		
2007	Dr. Leonard C. Harrison		
2008	Dr. Daniel Von Hoff		
2009	Dr. Camillo Ricordi		
2010	Dr. Paul Nurse		
2011	Dr. Linda Wicker		
2012	Dr. Joan S. Brugge		

2018 Dr. David M. Kovitz Visiting Professorship Lecture

Dr. Stanley Riddell

**Professor, Department of Medicine,
University of Washington**

**“The Development of Safe and Effective
Engineered T Cell Therapies for
Hematologic Malignancies”**

**Tuesday, September 18, 2018
1:00-2:00pm**

Theatre 4, HSC

**Reception: 2:00-3:00pm
HRIC Atrium**



**UNIVERSITY OF
CALGARY**



Dr. Stanley Riddell

Dr. Stanley Riddell, is a full member of the Program in Immunology of the Clinical Research Division at the Fred Hutchinson Cancer Research Center, and a professor in the Department of Medicine at the University of Washington. Dr. Riddell has been elected to the Association of American Physicians, and his current work builds on his previous accomplishments and seeks to identify further ways to improve the effectiveness of T cell immunotherapies.

Dr. Riddell is an expert in cell transplantations and T cell-based immunotherapies, and has used them to treat many patients with lymphoma and leukemia. He's contributed many advances that are widely used in cell-based immunotherapy approaches, including CAR T cells, and also led the first clinical trial that utilized adoptively transferred T cells.

Dr. Riddell's lab has developed critical techniques for isolation, expansion, genetic modification and reinfusion of therapeutic T cells, and for monitoring patient safety, T cell persistence, migration and function post-infusion. These include state-of-the-art ways to identify the tumor cell "antigens" recognized by T cells. Many are now broadly employed in adoptive immunotherapies for cancer that use natural targeting molecules called T cell receptors (TCRs) or use synthetic TCR- and antibody-related molecules known as chimeric antigen receptors (CARs).

Program

Welcoming Remarks

Dr. Greg Cairncross
Director, Charbonneau Cancer Institute

Introduction of Dr. Stanley Riddell

Dr. Doug Mahoney
Assistant Professor, University of Calgary

The 2018 Dr. David M. Kovitz Lecture

***"The Development of Safe and Effective
Engineered T Cell Therapies for Hematologic
Malignancies"***

Closing Remarks

Dr. Jennifer Chan
Deputy Director, Charbonneau Cancer Institute

Please join us for a reception in the HRIC Atrium